B. Riley Wealth Advisors Inc. increased its holdings in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 27,387 shares of the company’s stock after acquiring an additional 1,278 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Zoetis were worth $4,062,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of ZTS. Fairfield Bush & CO. acquired a new position in shares of Zoetis in the first quarter valued at approximately $134,000. Sequoia Financial Advisors LLC lifted its position in shares of Zoetis by 5.3% in the 1st quarter. Sequoia Financial Advisors LLC now owns 4,166 shares of the company’s stock worth $786,000 after purchasing an additional 211 shares during the period. Candriam Luxembourg S.C.A. increased its stake in shares of Zoetis by 3.9% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 51,581 shares of the company’s stock valued at $9,727,000 after acquiring an additional 1,914 shares in the last quarter. Covestor Ltd grew its stake in shares of Zoetis by 102.8% in the 1st quarter. Covestor Ltd now owns 724 shares of the company’s stock worth $137,000 after acquiring an additional 367 shares in the last quarter. Finally, Merit Financial Group LLC boosted its holdings in shares of Zoetis by 92.8% in the 1st quarter. Merit Financial Group LLC now owns 2,342 shares of the company’s stock worth $442,000 after buying an additional 1,127 shares during the last quarter. 90.23% of the stock is owned by institutional investors.
Zoetis Stock Performance
ZTS opened at $166.31 on Friday. Zoetis Inc. has a twelve month low of $124.15 and a twelve month high of $201.32. The company has a current ratio of 2.37, a quick ratio of 1.63 and a debt-to-equity ratio of 1.49. The stock has a market cap of $77.07 billion, a PE ratio of 36.96, a price-to-earnings-growth ratio of 2.53 and a beta of 0.76. The business’s 50 day moving average is $164.91 and its 200-day moving average is $155.22.
Zoetis Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 1st. Investors of record on Friday, April 21st will be given a dividend of $0.375 per share. The ex-dividend date of this dividend is Thursday, April 20th. This represents a $1.50 annualized dividend and a yield of 0.90%. Zoetis’s dividend payout ratio is presently 33.33%.
Analysts Set New Price Targets
A number of brokerages have commented on ZTS. Barclays increased their price target on shares of Zoetis from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Tuesday, February 21st. StockNews.com assumed coverage on Zoetis in a research note on Thursday. They issued a “buy” rating on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $223.83.
Zoetis, Inc engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Get Rating).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.